Current Price
Target Price
TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases. The company is headquartered in South San Francisco, California.
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
| Metric (B) | FY 2026 | FY 2026 | FY 2027 |
|---|---|---|---|
| $-0.61 | $-0.48 | $-1.72 | |
| 0 | 0 | 0 | |
| — | — | — |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | AAspen Neur... | ASPE | $366.10M | — | — | — | — | — | — |
| 2. | VVogenx Inc | VOGX | $247.63M | — | 3.07 | — | — | — | — |
| 3. | OOculis Hol... | OCSAW | — | — | — | — | — | — | — |
| 4. | PInternet P... | PTNT | — | — | — | — | — | — | — |
| 5. | PInternet P... | PTNT | — | — | — | — | — | — | — |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) |
|---|
Revenue |
COGS |
Gross Profit |
Gross Profit % |
EBIT |
OPM % |
Non-Operating Income |
PBT |
Income Tax |
Tax Rate % |
Net Income |
NPM % |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2024 | Dec 2025 |
|---|---|---|
Revenue | 39.11 | 0 |
COGS | 0 | 0 |
Gross Profit | 0 | 0 |
Gross Profit % | - | - |
| 41.49 | 37.84 | |
EBIT | -2.38 | -37.84 |
OPM % | -6.09% | - |
Non-Operating Income | 1.94 | 3.08 |
PBT | -0.44 | -34.76 |
Income Tax | 0 | 0 |
Tax Rate % | - | - |
Net Income | -3.14 | -34.81 |
NPM % | -8.04% | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2024 | Dec 2025 |
|---|---|---|
| 47.47 | 15.19 | |
| 17.84 | 52.53 | |
| 0 | 0 | |
| 0 | 0 | |
| 2.76 | 5.41 | |
Total Assets | 68.07 | 73.13 |
| 0 | 0 | |
| -57.97 | -92.12 | |
| 0 | 0 | |
| 0.68 | 0.65 | |
| 125.36 | 164.6 | |
Total Liabilities | 68.07 | 73.13 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2024 | Dec 2025 |
|---|---|---|
| -25.58 | -41.36 | |
| 0 | 0 | |
| 41.85 | 42.07 | |
Net CFNet Cash Flow | 16.27 | 0.71 |
FCFFree Cash Flow | -25.65 | -41.43 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2024 | Dec 2025 |
|---|---|---|
| - | 46.4% | |
| - | - | |
| 8.86 | 14.30 | |
| - | 0.00 | |
Cash Conversion | 8.14 | 1.19 |
Payout Ratio | - | - |
| - | -100.0% | |
| - | - | |
| - | - | |
| 1.00 | 2.00 | |
| - | - | |
| - | - | |
| -0.1% | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns Trex Bio Inc, from SEC filings
No SEC ownership filings for this company yet.
Trex Bio Inc's SEC filings and earnings call transcripts
No SEC filings for this company yet.
What recent news says about Trex Bio Inc, scored for sentiment.